Close

Axovant Sciences (AXON): Allergan Acquisition of Chase a Positive - Baird

Go back to Axovant Sciences (AXON): Allergan Acquisition of Chase a Positive - Baird

Baird Sees Minimal Read Through for Axovant (AXON) on Lilly's Sola Failure

November 23, 2016 12:26 PM EST

Baird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which was weaker on Lilly's solanezumab failure. The analyst sees no change for AXON and maintained an Outperform rating and price target of $29.

Skorney commented, "The Alzheimer's field was... More

Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - Piper

November 23, 2016 11:22 AM EST

Piper Jaffray analyst Charles Duncan said Lilly's solanezumab failure doesn't change their perception of risk for Axovant Sciences (NYSE: AXON) or vTv Therapeutics (NASDAQ: VTVT), noting these candidates have mechanisms that do not overlap with... More